Evidence map›Paper›PMID 20960353›Full record

ArticleActa neurochirurgica. Supplement2011

A technical description of the brain tumor window model: an in vivo model for the evaluation of intraoperative contrast agents.

Daniel A Orringer, Thomas Chen, Dah-Luen Huang, Martin Philbert, Raoul Kopelman, Oren Sagher

Abstract read
In one paragraph

Article in Acta neurochirurgica. Supplement, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel A OrringerDepartment of Neurosurgery, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-5338, USA.
Thomas Chen
Dah-Luen Huang
Martin Philbert
Raoul Kopelman
Oren Sagher

Funding

Role of Astrocyte Mitochondria in NeurotoxicityR01ES008846 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PHILBERT, MARTIN A. · 1999 to 2012
$4.7M
Nanoparticle Enabled Intraoperative Imaging and TherapyR01EB007977 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOPELMAN, RAOUL · 2007 to 2009
$2.8M
Nanobiophotonics Enabled Tumor Surgery and Intraoperative PDTR21CA125297 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOPELMAN, RAOUL · 2007 to 2007
$228k
Nanoparticle-Enabled Brain Tumor SurgeryF32CA126295 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ORRINGER, DANIEL · 2007 to 2008
$104k
NCI NIH HHS 1F32CA126295-01A1NCI NIH HHS 1R21CA125297-01A1NCI NIH HHS F32 CA126295NCI NIH HHS R21 CA125297NIBIB NIH HHS 1R01EB007977-01NIBIB NIH HHS R01 EB007977NIEHS NIH HHS R01 ES008846
6 · The paper itself

Abstract

The evaluation of candidate optical contrast agents for brain tumor delineation in ex vivo models may not accurately predict their activity in vivo. This study describes an in vivo model system designed to assess optical contrast agents for brain tumor delineation. The brain tumor window (BTW) model was created by performing biparietal craniectomies on 8-week-old Sprague-Dawley rats, injecting 9L glioma cells into the cortex and bonding a cover slip to the cranial defect with cyanoacrylate glue. Tumor growth was followed serially and occurred in an exponential fashion. Once tumors on the cortical surface achieved a 1mm radius, intravenous contrast agents were injected while the appearance of the cortical surface was recorded. Computerized image analysis was used to quantitatively evaluate visible differences between tumor and normal brain. Tumor margins became readily apparent following contrast administration in the BTW model. Based on red component intensity, tumor delineation improved fourfold at 50 min post-contrast administration in the BTW model (P<0.002). In summary, window placement overlying an implanted glioma is technically possible and well tolerated in the rat. The BTW model is a valid system for assessing the in vivo activity of optical contrast agents.

Indexed as

Contrast MediaRosaniline DyesAnimalsBrain MappingBrain NeoplasmsCell Line, TumorDisease Models, AnimalDisease ProgressionGliomaImage Processing, Computer-AssistedMagnetic Resonance ImagingMonitoring, IntraoperativeRatsRats, Sprague-DawleyContrast MediaCoomassie blueRosaniline Dyes

Identifiers

PMID20960353
PMCPMC4438080

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.